EQUITIES

Robust. Fundamental. Dynamic.

Our teams exercise independent thought with high conviction, resulting in portfolios that we believe are well positioned to address our clients' challenges – all within robust risk control frameworks.

vd-icon_Currency_CashUSD

$237.1bn
Equities Assets Under Management

vd-icon_People_3_Group v3

153
Equities Investment
Professionals

vd-icon_Bulleye_Target v3

19
Average Years’ Financial
Industry Experience

As at 30 September 2024

<span class="notranslate">no data</span>

$237.1bn
Equities Assets Under Management

153
Equities Investment
Professionals

19
Average Years’ Financial
Industry Experience

As at 30 September 2024

We measure success by a single factor: client outcomes. As a pure asset manager, our sole mission is to deliver consistent long-term risk-adjusted returns that exceed our benchmarks and peers, regardless of the prevailing investment landscape.

Featured strategies

Global Life Sciences

By understanding the science and business of health care, our experienced team seeks to invest in companies addressing unmet medical needs or improving efficiencies.

Biotechnology Innovation

A biotechnology strategy that seeks to leverage a disciplined approach to identify compelling opportunities across the biotech landscape in both public and private investments

Global Technology Leaders

A global approach to investing in technology companies from a highly experienced team



Insights

More lights are turning green for listed real estate in 2025

Guy Barnard discusses the alignment of multiple supportive factors for listed REITs in 2025.

Secular growth drivers align for emerging market equities

Daniel Graña sees a compelling case for long-term investors to maintain an allocation to emerging market equities.

Global themes are where European equities can find their magic

Portfolio Manager Tom O’Hara discusses favourable geopolitical dynamics and a potential cyclical recovery for European equities in 2025.